Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranilast in Duchenne Muscular Dystrophy (Phase II, Japan)
jRCT2051230201Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Duchenne muscular dystrophy (DMD) comparing Tranilast with Placebo (2 arms). Primary endpoints: Performance of Upper Limb (PUL) version 2.0 total score, %FVC (percent predicted forced vital capacity) and 2 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
tranilast
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on jRCT2051230201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230201.